Журнал кардиореспираторных исследований 2026. №2/3

Тема статьи

Tizimli qizil yuguriq: epidemiologiya, patogenez, tashxis va zamonaviy davolash yondashuvlari (92-95)

Авторы

Xusanov M.U., Ergashova M.M.

Учреждение

Samarqand davlat tibbiyot universiteti

Аннотация

Tizimli qizil yuguriq (TQY) — immunologik tolerantlikning buzilishi va yadroviy antigenlarga qarshi autoantitelolar hosil bo'lishi natijasida rivojlanadigan, ko'p organlarni zararlovchi surunkali autoimmun kasallikdir. Epidemiologik ma'lumotlarga ko'ra, TQY tarqalishi 100 000 aholiga nisbatan 20–150 holat tashkil etib, reproduktiv yoshdagi ayollar orasida kasallanish ko'rsatkichi sezilarli darajada yuqori. Patogenezida apoptotik klirens defektlari, I tipdagi interferon signal yo'llarining faollashuvi, B- va T-hujayra tolerantligining buzilishi hamda to'qimalardagi immun komplekslarning cho'kishi muhim o'rin tutadi. Klinik ko'rinishlari juda xilma-xil — teri va bo'g'im shikastlanishidan hayot uchun xavfli visseral asoratlargacha. Zamonaviy davolash strategiyasi gidroksiхlorokin, glyukokortikoidlar, immunosupressivlar va biologik preparatlar (belimumab, anifrolumab) yordamida remissiyaga erishish va uni saqlashga asoslanadi.

Ключевые слова

tizimli qizil yuguriq, autoimmunitet, antinuklear antitelolar, I tipdagi interferon, lupus nefriti, biologik terapiya.

Литературы

1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110–2121. doi: 10.1056/NEJMra1100359. 2. Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol. 2015;11(6):329– 341. doi: 10.1038/nrneph.2015.33 3. Immunology of SLE. Craft JE. Follicular helper T cells in immunity and systemic autoimmunity. Nat Rev Rheumatol. 2012;8(6):337–347. 4. Izmirly PM, Wan I, Sahl S, et al. The incidence and prevalence of systemic lupus erythematosus in New York County (Manhattan), New York. Arthritis Rheumatol. 2017;69(10):2006–2017. 5. Nasonov EL, Soloviev SK. Tizimli qizil yuguriq. In: Revmatologiya. Moscow: GEOTAR-Media; 2020. pp. 456–520. 6. Ronnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med. 2019;6(1):e000270. 7. Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825–835. doi: 10.2215/CJN.05780616 8. Khamashta M, Furie R, Bhd M, et al. Anifrolumab, an anti–interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376–386. 9. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine. 2003;82(5):299–308. 10. Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1). Lancet. 2021;397(10289):2070–2080. 11. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151–1159. 12. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745. 13. Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117–1128.